이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Akebia Therapeutics 대차 대조표 상태

재무 상태 기준 확인 2/6

Akebia Therapeutics 의 총 주주 지분은 $-27.3M 이고 총 부채는 $85.6M, 이는 부채 대 자기자본 비율을 -314.2% 로 가져옵니다. 총자산과 총부채는 각각 $225.5M 및 $252.7M 입니다.

주요 정보

-314.2%

부채 비율

US$85.64m

부채

이자 보상 비율	n/a
현금	US$41.96m
주식	-US$27.26m
총 부채	US$252.74m
총 자산	US$225.48m

최근 재무 상태 업데이트

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Jun 24

Recent updates

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

May 26

재무 상태 분석

단기부채: AKBA 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: AKBA 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: AKBA 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: AKBA 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: AKBA 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: AKBA 무료 현금 흐름이 역사적 비율인 11 로 계속 증가할 경우 1 년 동안 충분한 현금 활주로를 보유하고 있습니다. 11 % 매년.

Akebia Therapeutics 대차 대조표 상태

재무 상태 기준 확인 2/6

주요 정보

최근 재무 상태 업데이트

Akebia Therapeutics, Inc. announced delayed 10-Q filing

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics, Inc. Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq

Akebia Therapeutics Receives Non-Compliance Notice from Nasdaq

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?

Recent updates

Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates decrease by 13%

First quarter 2024 earnings released: US$0.088 loss per share (vs US$0.14 loss in 1Q 2023)

Akebia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Akebia Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Profitability

No longer forecast to breakeven

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Full year 2023 earnings: EPS exceeds analyst expectations

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Akebia Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

CEO, President & Director recently sold US$74k worth of stock

CEO, President & Director notifies of intention to sell stock

Price target increased by 12% to US$4.33

CEO, President & Director recently sold US$78k worth of stock

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Price target increased by 29% to US$3.88

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023

Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023

Akebia Therapeutics, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Akebia Therapeutics, Inc. announced delayed 10-Q filing

Akebia Therapeutics, Inc. Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia®? (ferric Citrate) for In-Center and Home Dialysis Patients

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Akebia Therapeutics, Inc. Announces Swissmedic Approval of Vafseo Vadadustat

Akebia Therapeutics, Inc. Announces Executive Changes

Senior VP & COO recently sold US$117k worth of stock

Consensus estimates of losses per share improve by 15%

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akebia Therapeutics, Inc. Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Principal Accounting Officer recently sold US$68k worth of stock

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.33 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023

Price target increased by 23% to US$2.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director recently sold US$81k worth of stock

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics, Inc. Receives Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA

Akebia Therapeutics, Inc. Announces Executive Changes

Insufficient new directors

Akebia Therapeutics, Inc. Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2022

Akebia Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Consensus forecasts updated

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with Covid-19 and Hypoxemia (VSTAT)

Akebia Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target decreased to US$1.63

Insufficient new directors

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Akebia Therapeutics Receives Non-Compliance Notice from Nasdaq

Akebia Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Akebia Therapeutics, Inc

Akebia Therapeutics, Inc. Approves Reduction of the Workforce by Approximately 42%